Article
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Cancer cell - 12 Jan 2015
Hill Rebecca M, Kuijper Sanne, Lindsey Janet C, Petrie Kevin, Schwalbe Ed C, Barker Karen, Boult Jessica K R, Williamson Daniel, Ahmad Zai, Hallsworth Albert, Ryan Sarra L, Poon Evon, Robinson Simon P, Ruddle Ruth, Raynaud Florence I, Howell Louise, Kwok Colin, Joshi Abhijit, Nicholson Sarah Leigh, Crosier Stephen, Ellison David W, Wharton Stephen B, Robson Keith, Michalski Antony, Hargrave Darren, Jacques Thomas S, Pizer Barry, Bailey Simon, Swartling Fredrik J, Weiss William A, Chesler Louis, Clifford Steven C
Abstract excerpt
We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all patients in this group died of rapidly progressive disease postrelapse. To study this interaction, we investigated a transgenic model of MYCN-driven medulloblastoma and found...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.